John Fry

2.4k total citations
35 papers, 621 citations indexed

About

John Fry is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, John Fry has authored 35 papers receiving a total of 621 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 14 papers in Hepatology and 8 papers in Infectious Diseases. Recurrent topics in John Fry's work include Hepatitis C virus research (14 papers), Hepatitis B Virus Studies (10 papers) and Liver Disease Diagnosis and Treatment (8 papers). John Fry is often cited by papers focused on Hepatitis C virus research (14 papers), Hepatitis B Virus Studies (10 papers) and Liver Disease Diagnosis and Treatment (8 papers). John Fry collaborates with scholars based in United States, France and Belgium. John Fry's co-authors include Anil Singhal, Han Ting Ding, Frits van Rhee, Daniel Afar, Jeffrey A. Zonder, Seema Singhal, William Bensinger, Ann Mohrbacher, Oliver Lenz and Fabien Zoulim and has published in prestigious journals such as Blood, Gastroenterology and Contemporary Sociology A Journal of Reviews.

In The Last Decade

John Fry

33 papers receiving 597 citations

Peers

Countries citing papers authored by John Fry

Since Specialization

Citations

This map shows the geographic impact of John Fry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Fry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Fry more than expected).

Fields of papers citing papers by John Fry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Fry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Fry. The network helps show where John Fry may publish in the future.

Co-authorship network of co-authors of John Fry

This figure shows the co-authorship network connecting the top 25 collaborators of John Fry. A scholar is included among the top collaborators of John Fry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Fry. John Fry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants 2025 ·Antiviral Therapy ·Edward Gane, Christian Schwabe, Min Wu, Tse‐I Lin, Lawrence M. Blatt, John Fry, Sushmita Chanda, Kha Le	0
2	Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results 2023 ·PLoS ONE ·(unknown), Matthew W. McClure, Julian Symons, Sushmita Chanda, John Fry, Patrick F. Smith, (unknown), Michaël Fayon, Kulkanya Chokephaibulkit, Rattapon Uppala, Jolanta Bernatoniene, Kenji Furuno, Thorsten Stanley, Dymphy Huntjens, James Witek, (unknown)	14
3	Nomenclature of HBV core protein-targeting antivirals 2022 ·Nature Reviews Gastroenterology & Hepatology ·Fabien Zoulim, Adam Zlotnick, Stephanie Buchholz, Eric Donaldson, John Fry, Anuj Gaggar, Jianming Hu, Michael Kann, Oliver Lenz, Kai Lin, Nagraj Mani, Michael Nassal, William E. Delaney, Su Wang, Gabriel Westman, Veronica Miller, Harry L.A. Janssen	40
4	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection 2020 ·Gastroenterology ·Fabien Zoulim, Oliver Lenz, Joris Vandenbossche, Willem Talloen, Thierry Verbinnen, Iurie Moscalu, Adrian Streinu‐Cercel, Stefan Bourgeois, Marı́a Buti, Javier Crespo, J.M. Pascasio, Christoph Sarrazin, Thomas Vanwolleghem, Umesh Shukla, John Fry, Jeysen Yogaratnam	85
5	Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects 2018 ·PLoS ONE ·Matthew W. McClure, Elina Berliba, Tengiz Tsertsvadze, Adrian Streinu‐Cercel, Leen Vijgen, B Astruc, Alain Patat, Christopher Westland, Sushmita Chanda, Qingling Zhang, Thomas N. Kakuda, (unknown), (unknown), Leonid Beigelman, Lawrence M. Blatt, John Fry	8
6	Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis 2018 ·Hepatology ·Edward Gane, Catherine Stedman, Christian Schwabe, Leen Vijgen, Sushmita Chanda, Thomas N. Kakuda, John Fry, Lawrence M. Blatt, Matthew W. McClure	3
7	Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans 2018 ·Journal of Antimicrobial Chemotherapy ·Kashyap Patel, Carl M. J. Kirkpatrick, Keith Nieforth, Sushmita Chanda, Qingling Zhang, Matthew W. McClure, John Fry, Julian Symons, Lawrence M. Blatt, Leo Beigelman, John P. DeVincenzo, Dymphy Huntjens, Patrick F. Smith	28
8	AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients 2016 ·Journal of Hepatology ·Elina Berliba, Tengiz Tsertsvadze, (unknown), D. Guyader, (unknown), C. Westland, Sushmita Chanda, Alain Patat, (unknown), David A. Smith, Jeysen Yogaratnam, Myra O. McClure, Leo Beigelman, (unknown), John Fry	3
9	866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE 2–4 CHRONIC HEPATITIS C 2013 ·Journal of Hepatology ·Patrick Marcellin, Simona Georgiana Popa, Adrian Streinu‐Cercel, (unknown), (unknown), Alain Patat, (unknown), Varun Garg, Robert S. Kauffman, Margaret James Koziel, Myron J. Tong, Sushmita Chanda, (unknown), C. Westland, Leo Beigelman, (unknown), John Fry	3
10	A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma 2011 ·Blood ·Jeffrey A. Zonder, Ann Mohrbacher, Seema Singhal, Frits van Rhee, William Bensinger, Han Ting Ding, John Fry, Daniel Afar, Anil Singhal	277
11	Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results. 2009 ·Blood ·Sagar Lonial, Ravi Vij, Jean‐Luc Harousseau, Thierry Façon, Jonathan L. Kaufman, Amitabha Mazumder, Philippe Moreau, Xavier Leleu, John Fry, Anil Singhal, Sundar Jagannath	15
12	Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects 2002 ·Journal of Hepatology ·Brian P. Kearney, W B Knight, Graeme Currie, (unknown), Ramin Ebrahimi, Stan Gill, John Fry, Carol Brosgart	6
13	Reviving Primary Care: A US-UK Comparison 1999 ·Journal of Public Health Policy ·Bárbara Starfield, John Fry, Donald W. Light, Jonathan E Rodnick, Peter Orton	1
14	Self-medication in Europe : report on a study of the role of non-prescription medicines 1988 ·Lowell S. Levin, (unknown), John Fry	9
15	Limits of the Welfare State: Critical Views on Post-War Sweden. 1981 ·Contemporary Sociology A Journal of Reviews ·John Stephens, John Fry	8
16	Deaths and complications from hypertension. 1975 ·PubMed ·John Fry	8
17	The Aftermath of Otitis Media 1970 ·Proceedings of the Royal Society of Medicine ·John Fry	2
18	Provision of General Medical Care in New Towns 1967 ·RePEc: Research Papers in Economics ·John Fry, (unknown)	0
19	CARDIOVASCULAR DISEASE: 1. 1963 ·PubMed ·(unknown), John Fry	4
20	Neurosis in General Practice 1955 ·BMJ ·John Fry	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact